John E Kao

CEO John E Kao sells 298,000 shares (298.0K) for $6,066,620.78 via scheduled 10b5-1 plan

John E Kao, CEO of Alignment Healthcare, executed 2 separate sales totaling 298,000 shares for $6,066,620.78 on 2026-06-10, reducing his post-transaction holdings to 1,386,766 shares (-17.7% vs pre-transaction holdings). This transaction is part of a pre-arranged 10b5-1 trading plan and therefore reflects a scheduled, non-discretionary execution rather than a discretionary decision made at this moment. The company trades at a P/E of 197.50 and reported full-year net income that was negative despite quarterly revenue of $1,235,197,000.00 and strong FY revenue growth of +46.1%, indicating significant unprofitability at the consolidated level. His prior five trades at ALHC show mixed outcomes, with two May sells showing +22.0% and +17.2% 30-day returns followed by three April sales showing negative 30-day returns (-12.2%, -12.9%, -16.1%), suggesting volatility in near-term stock performance around his trading activity.

ALHC CEO John Kao sells roughly 298k shares in two tranches; stock trading well below 52-week highs amid unprofitable fundamentals.

CEO John Kao disposed of approximately 298,000 shares across two transactions, reducing his stake by a combined sixteen percent—a material liquidation for a top executive. This sale is the sixth and seventh of Kao's open-market exits at ALHC over the past three years, underscoring a consistent seller posture. The company remains unprofitable despite strong revenue growth, and the stock is trading well below its 52-week high while down over the past month, creating an unfavorable backdrop for executive selling. What stands out is Kao's execution track record: his five prior sales at ALHC were all well-timed at both the 30-day and 90-day horizons—in each case the stock declined after he sold—suggesting he has successfully identified weak periods to exit. Placing these two additional sales in that consistent pattern raises a question about whether near-term price weakness signals operational headwinds the market has not yet fully priced in.

CEO John E. Kao sold 298,000 shares (298.0K shares) for $6,161,942.61 across 3 transactions at blended average $20.68

John E. Kao, CEO of Alignment Healthcare, executed 3 separate sales totaling 298,000 shares for $6,161,942.61 on April 10 and April 13, 2026, reducing his holdings by 14.2% to 1,806,641 shares. The company trades at a P/E of 40.35 with 46.1% annual revenue growth but reported negative full-year net income, presenting a high-valuation growth profile balanced against unprofitability concerns. At his same ticker (ALHC), Kao's 5 prior trades in March and early April have not yet demonstrated measurable 90-day outcomes; his cross-ticker track record shows a 90-day well-timed sell rate of 41.67%, indicating mixed historical execution. The current share price of $20.98 remains 11.9% below the 52-week high of $23.81, and the sales occurred after the stock gained +23.5% over the preceding 30 days, suggesting sales during a period of recent strength.

CEO Kao sells 250,000 shares (10.6% of holdings) at blended average $21.01; stock up 17.0% in 30 days but CEO has 25.00% well-timed sell rate cross-ticker.

John E. Kao, Chief Executive Officer of Alignment Healthcare, Inc., executed 2 separate sales totaling 250,000 shares for $5,252,910.60 on 2026-04-07, bringing his post-transaction holdings to 2,104,641 shares. The sales occurred at $20.67 and $21.40 per share (blended average $21.01), in a market context where the stock is currently at $21.31 and has risen 17.0% over 30 days. Across his open-market trade history on all tickers, Kao has achieved a 25.00% well-timed sell rate (90-day basis), suggesting a pattern of identifying peaks; however, his 5 prior trades at ALHC remain too recent to measure outcomes. The company is currently trading at a P/E of 40.98 with recent quarterly revenue of $993,695,000.00, though it was unprofitable over its most recent full fiscal year.

CEO John E Kao sells 118,000 ALHC shares at $17.48; stock down 15% in 30d, 26.5% from 52w high.

CEO John E Kao sold 118,000 shares (118.0K shares) at $17.48 on 2026-03-23, reducing his stake from 2,472,641 shares (2.47M shares) to 2,354,641 shares (2.35M shares). The sale occurs amid sharp recent price deterioration: the stock is down 15.0% over the prior 30 days and trades 26.5% below its 52-week high of $23.81. The CEO's same-ticker history at ALHC shows five recent sales in rapid succession (three on 2026-03-12, plus sales on 2026-03-18, 2026-03-10, and 2026-02-10), with the only measurable outcome (2026-02-10 sale) showing a 30-day decline of 16.4%. His cross-ticker track record across 20 prior sells shows an average 90-day return of +14.5% and a 90d well-timed rate of 18.18%, but at ALHC specifically, none of the prior sells achieved positive 90-day returns (0 of 0 prior sells were well-timed at the 90-day mark). Fundamentally, while the company achieved 46.1% annual revenue growth, it remains unprofitable (full-year net income was negative despite latest quarterly net income of $3.7M), and the stock trades at a P/E of 33.67.

CEO John E. Kao sold 73,046 shares of ALHC at $17.84; stock down -23.7% from 52-week high. Pattern: 5 ALHC sales in 6 weeks, 0 well-timed.

CEO John E. Kao executed his third sale of Alignment Healthcare shares in six days (March 10, 12, and 18), the most recent a 73,046-share sale at $17.84. The stock currently sits -23.7% from its 52-week high of $23.81 and has fallen -11.8% in 30 days and -11.1% in 90 days. Notably, Kao has sold ALHC shares on five separate occasions within a two-month window (January 12 through March 18), yet his prior same-ticker sales show a 0% well-timed rate—of the measurable outcomes, the stock rose after his prior sales, not fell. His broader cross-ticker track record shows 25% well-timed sell outcomes over 20 prior transactions, making his recent ALHC activity an outlier at this company. The frequency of these sales, combined with the stock's sharp recent decline and the company's full-year unprofitability despite strong 46.1% annual revenue growth, warrants attention to whether multiple sales by the CEO signal operational headwinds or a shift in his conviction.

CEO sells 48,899 shares ($853.1K) at blended $17.45; stock down 16.7% in 30 days, 28.6% from 52-week high.

John E. Kao, CEO of Alignment Healthcare, executed two separate sales on March 12, 2026, totaling 48,899 shares for $853,125.51 (blended average $17.45). His post-transaction holdings remain substantial at 1,519,480 shares (1.52M shares). The timing context is notable: the stock has declined 16.7% over the past 30 days and trades 28.6% below its 52-week high of $23.81, suggesting the CEO sold into a period of deteriorating price momentum. His prior trades at ALHC show a 0% well-timed rate at the 90-day mark (all measurable outcomes resulted in stock gains after his sales), though recent 30-day outcomes have been mixed (ranging from -16.4% to +18.0%). The company remains unprofitable on a full-year basis despite strong revenue growth of 46.1%, and the stock currently trades at a P/E of 32.67—elevated multiples on negative profitability. The sale itself represents a 3.1% reduction in his ALHC holdings but does not constitute a complete exit.

CEO John E. Kao sells 180,000 shares of ALHC for $3.3M on March 10, 2026; stock down -24.0% from 52-week high.

CEO John E. Kao sold 180,000 shares at $18.19, reducing holdings from 2.65M to 2.47M shares. The stock has since declined 16.8% over 30 days and trades 24.0% below its 52-week high of $23.81, currently at $18.10. At ALHC specifically, Kao's prior five trades show no measurable 90-day outcomes yet (the most recent comparable prior sale on 2026-01-12 delivered -5.5% over 30 days). His cross-ticker track record across 20 prior sells shows a 40% well-timed rate and average 90-day return of +5.5%, indicating mixed historical timing precision. The company remains unprofitable on a full-year basis despite strong 46.1% annual revenue growth and $993.7M quarterly revenue; at $3.7B market cap with P/E of 34.81, the valuation reflects significant growth expectations. The sale's timing against the stock's recent downward trajectory and distance from 52-week highs warrants attention to whether further deterioration may follow, though the lack of measurable history at this ticker limits comparative insight into Kao's predictive accuracy at ALHC.

CEO John E Kao sold 180,000 shares of ALHC at $20.49 for $3.7M on 2026-02-10

CEO John E Kao sold 180,000 shares (6.4% of pre-transaction holdings) at $20.49, reducing his stake to 2,652,641 shares. At same-ticker history, his five prior ALHC sales have yielded positive 30-day returns (+13.9%, +18.0%, +9.3%), but none have yet produced measurable 90-day outcomes to evaluate timing precision. Across his broader cross-ticker track record, prior sells averaged a positive 90-day return of +4.9%, indicating the market generally moved upward after his exits, and his well-timed rate of 40.00% suggests his sales are timed below market-timing benchmark. The company's fundamentals show $993.7M quarterly revenue with +48.2% annual growth, but it remains unprofitable (negative full-year net income), creating a disconnect between revenue trajectory and profitability. The stock is currently -13.4% from its 52-week high of $23.81, suggesting the CEO is selling into a modest downtrend from its peak, though up +24.3% over the trailing 90 days.

CEO John E. Kao sells 180,000 ALHC shares for $3.8M at $21.11 blended average; post-sale holding 2.83M shares

CEO John E. Kao executed 2 separate sales totaling 180,000 shares for $3,799,218.97 on 2026-01-12, reducing his holding from 3,012,641 shares to 2,832,641 shares (-6.0%). The sales occurred at a blended average price of $21.11, near the current price of $21.74 (the 52-week high), following a 90-day rally of +28.0%. At the same-ticker level, Kao's prior 5 trades at ALHC show mixed outcomes: of 1 measurable prior sale (2025-10-10), the 90-day return was +21.2%, indicating that prior sale was poorly timed (stock rose after). His cross-ticker track record across 20 prior sells shows an average 90-day return of +1.7% with a 50% well-timed rate, suggesting modest historical execution. The company reported $993.7M in quarterly revenue with +48.2% annual growth, but remains unprofitable on a full-year basis (net income negative). The timing of this sale at the 52-week high, combined with strong recent momentum and the pattern of post-sale stock appreciation in his recent same-ticker history, merits observation of whether this signals a view shift or is circumstantial to his broader holding management.